Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AMAG Pharmaceuticals, Inc reaffirms FY 2014 revenue guidance; issues FY 2014 earnings guidance below analysts' estimates


Thursday, 24 Apr 2014 07:03am EDT 

AMAG Pharmaceuticals, Inc:Expects FY 2014 total revenues of between $88 mln and $100 mln.Expects FY 2014 net loss (GAAP) in the range of $10 mln to $12 mln.Expects FY 2014 positive adjusted EBITDA (non-GAAP) of $10 mln to $13 mln.FY 2014 revenue of $95 mln, net income of $(1.08) mln and EBITDA of $(1.97) mln - Thomson Reuters I/B/E/S. 

Related Company News

Company Quote

19.09
-0.45 -2.30%
31 Jul 2014